Automated squeeze test (Gaenslen’s manoeuvre) to identify patients with arthralgia suspicious for progression to RA: improving time delay to rheumatology consultation

We read with interest the article by van Steenbergen et al and the response by Mankia et al. In the former, a definition of suspicious arthralgia was proposed and in the latter a new approach to identifying individuals at risk of progression to rheumatoid arthritis (RA) was discussed. We agree with Mankia et al that general practitioners (GPs) are the first contact for those patients at risk. In other countries a delay in referring patients with RA has been seen, and we have similarly detected a delay of 28.2 (SD 46.9) months. Thus, we are interested in clinical signs that allow GPs to identify patients with arthralgia suspicious for progression to RA—particularly, use of the squeeze test (ST) (also known as Gaenslen’s compression test). Previously, we found that the ST was useful in identifying RA progression in patients with undifferentiated arthritis in a year of follow-up.

Because of the importance of physical examination and also medical education, we devised a study protocol. In the first phase, we noted the variations in the ST results by certified rheumatologists, and found important differences. This supports the observations of van Steenbergen et al about the importance of clinical expertise and its reliability for diagnosing patients with arthritis. In the second phase, having found differences in performance of the test, we constructed an automated device to evaluate the ST performance. We carried out a study in patients with established RA and in healthy individuals. The median squeeze force necessary to evoke pain in the RA group was 3.07 (IQR 2.4) kg and 2.78 (IQR 3.8) kg in the right and left hand, respectively; and in the healthy group these values were 4.2 (IQR 9.5) kg and 4.6 (9.7) kg.

Mankia et al, in their study, sought to reduce the impact of clinical inexperience by using the anti-cyclical citrullinated peptide test for the detection of individuals at risk of RA. However, the cost–benefit of this test is controversial and several causes contribute to the dearth of such specialised studies—for example, inadequate clinical expertise of the first contact physician, inadequate number of rheumatologists in a given population, long waiting times for evaluation or even economic factors. The automated test could reduce this gap. The force of the ST which is applied to distinguish between a healthy individual, and a patient with active disease is already established. The strength of the squeeze needed to screen the patient with arthralgia which it is suspected will progress to RA is in the process of determination. The objective of all investigations is to develop an easy to use, cheap tool that can identify RA in patients at an early stage.

REFERENCES